Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02251275 · ClinicalTrials.gov registry record · Phase 3
Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
A Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,803
- Enrollment target
NCT02251275 is a Phase 3 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 1,803 participants.
The verdict
NCT02251275, a Phase 3 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,803 participants
- Enrollment target
Study Summary
The purpose of the trial was to evaluate and describe the long term safety of tolvaptan in participants with autosomal dominant polycystic kidney disease (ADPKD).
Interventions
- DRUG Tolvaptan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,803 participants |
| Start Date | 2014-10-17 |
| Est. Completion | 2018-11-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02251275
The ClinicalTrials.gov registry entry for NCT02251275 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,803 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tolvaptan is the first listed.
NCT02251275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02251275 about?
NCT02251275 is a clinical study titled "Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease". The purpose of the trial was to evaluate and describe the long term safety of tolvaptan in participants with autosomal dominant polycystic kidney disease (ADPKD).
What is the current status of trial NCT02251275?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,803 participants. The study started on 2014-10-17. Estimated completion is 2018-11-09.
What interventions are being tested in trial NCT02251275?
The interventions under investigation include: Tolvaptan (DRUG).
Who is sponsoring clinical trial NCT02251275?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.